Spectral Medical Reaches Milestone in Tigris Trial with Strong 2024 Enrollment

The latest announcement is out from Spectral Medical ( (TSE:EDT) ).

Spectral Medical has announced a robust close to 2024 for its Tigris trial, a Phase 3 study evaluating Polymyxin B Hemoperfusion in treating endotoxemia and septic shock. With 140 patients enrolled by year-end, enrollment surpassed expectations despite supply chain disruptions caused by Hurricane Helene. The company anticipates reaching full enrollment by the end of Q1 2025, signaling significant progress in its quest for FDA approval. This advancement in the Tigris trial could reinforce Spectral’s positioning in the biomedical industry, potentially benefiting stakeholders by addressing the critical need for effective sepsis treatments.

More about Spectral Medical

Spectral Medical Inc. is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock. It seeks U.S. FDA approval for its innovative product Toraymyxin (PMX), a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, guided by its Endotoxin Activity Assay (EAA), the only FDA-cleared diagnostic for sepsis risk. PMX is approved for use in Japan and Europe and has been used on over 340,000 patients, with exclusive development and commercial rights in the U.S. and Canada.

YTD Price Performance: 2.71%

Average Trading Volume: 13,505

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $108.6M

For an in-depth examination of EDT stock, go to TipRanks’ Stock Analysis page.